Stocks · News reference
BTIG Raises Price Target on United Therapeutics
BTIG maintained a Buy rating on United Therapeutics and increased its price target from $728 to $768.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RBC Raises Price Target on United Therapeutics to $725
RBC Capital Markets increased its price target for United Therapeutics Corporation from $697 to $725 while maintaining an Outperform rating.
United Therapeutics Announces Acquisition of Pfizer Royalty Interest in Ralinepag
United Therapeutics has agreed to pay $525 million to eliminate its future royalty obligations to Pfizer related to the experimental lung disease therapy ralinepag.
United Therapeutics Reports Third Quarter 2026 Financial Results
United Therapeutics Corporation announced its financial results for the third quarter of 2026, highlighting record revenue performance and a positive growth outlook.
United Therapeutics Announces New $2 Billion Share Repurchase Authorization
Alongside its third-quarter financial results, United Therapeutics Corporation announced a new $2 billion share repurchase authorization.
8-K filing — UNITED THERAPEUTICS Corp (UTHR)
Filed: 2026-11-04 AccNo: 0001082554-26-000036 Size: 431 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits